ES2134926T3 - Derivados vinileno-azaindolicos y su procedimiento de preparacion. - Google Patents

Derivados vinileno-azaindolicos y su procedimiento de preparacion.

Info

Publication number
ES2134926T3
ES2134926T3 ES94903774T ES94903774T ES2134926T3 ES 2134926 T3 ES2134926 T3 ES 2134926T3 ES 94903774 T ES94903774 T ES 94903774T ES 94903774 T ES94903774 T ES 94903774T ES 2134926 T3 ES2134926 T3 ES 2134926T3
Authority
ES
Spain
Prior art keywords
hydrogen
azaindolic
vinylene
derivatives
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903774T
Other languages
English (en)
Inventor
Franco Buzetti
Angelo Crugnola
Dario Ballinari
Felicita Greco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2134926T3 publication Critical patent/ES2134926T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LOS COMPUESTOS DE LA FORMULA (I) EN LA QUE UNO DE LOS GRUPOS DE X1 A X4 ES N Y LOS OTROS SON CH; R ES UN GRUPO DE FORMULA (A), (B), (C), (D) O (E) EN LAS QUE N ES CERO O UN ENTERO DE 1 A 5; R1 ES HIDROGENO, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, NITRO O UN GRUPO -NR4R5 EN EL QUE CADA R4 Y R3 ES INDEPENDIENTEMENTE HIDROGENO O ALQUILO C1-C6; R2 ES HIDROGENO, ALQUILO C1-C6 O ALCANOILO C1-C6; R3 ES HIDROGENO, HALOGENO, HIDROXI, ALCOXI C1-C6, CARBOXI, NITRO O UN GRUPO -NR4R5, EN EL QUE R4 Y R5 SON COMO SE HA DEFINIDO ANTERIORMENTE Y A LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. LOS COMPUESTOS DE LA FORMULA (I) SON UTILES COMO INHIBIDORES DE LA QUINASA DE TIROSINA.
ES94903774T 1992-12-23 1993-12-15 Derivados vinileno-azaindolicos y su procedimiento de preparacion. Expired - Lifetime ES2134926T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226855A GB9226855D0 (en) 1992-12-23 1992-12-23 Vinylene-azaindole derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
ES2134926T3 true ES2134926T3 (es) 1999-10-16

Family

ID=10727139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903774T Expired - Lifetime ES2134926T3 (es) 1992-12-23 1993-12-15 Derivados vinileno-azaindolicos y su procedimiento de preparacion.

Country Status (24)

Country Link
US (1) US5397787A (es)
EP (1) EP0626963B1 (es)
JP (1) JP3507497B2 (es)
KR (1) KR950700296A (es)
CN (1) CN1093707A (es)
AT (1) ATE181074T1 (es)
AU (1) AU670488B2 (es)
CA (1) CA2126228A1 (es)
DE (1) DE69325262T2 (es)
DK (1) DK0626963T3 (es)
ES (1) ES2134926T3 (es)
FI (1) FI943838A0 (es)
GB (1) GB9226855D0 (es)
GR (1) GR3030941T3 (es)
HU (1) HUT67431A (es)
IL (1) IL108087A (es)
MX (1) MX9400206A (es)
MY (1) MY109695A (es)
NZ (1) NZ259330A (es)
PL (1) PL304894A1 (es)
RU (1) RU94040390A (es)
TW (1) TW296383B (es)
WO (1) WO1994014808A1 (es)
ZA (1) ZA939578B (es)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5587385A (en) * 1991-12-24 1996-12-24 Farmitalia Carlo Erba S.R.L. Arylidene-heterocyclic derivatives and process for their preparation
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
WO1996032391A1 (de) * 1995-04-11 1996-10-17 Lonza Ag Verfahren zur herstellung von azaindolen mit aktiviertem kupferchromit katalysator durch katalytische dehydrocyclisierung von alkyl-pyridylaminen (pyridopyridinen)
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2222545A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
JP2002511852A (ja) * 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
AU8689298A (en) 1997-08-05 1999-03-01 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US20040067531A1 (en) * 1997-08-20 2004-04-08 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
HUP0004024A3 (en) 1997-09-26 2001-10-29 Zentaris Gmbh Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
US5935626A (en) * 1997-11-24 1999-08-10 Moorman Manufacturing Company Weather resistant mineral feeds and methods of making same
CA2318403A1 (en) 1998-01-21 1999-07-29 Sugen, Inc. Human orthologues of wart
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
WO1999048868A2 (en) * 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
CA2369172A1 (en) 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
JP2002523455A (ja) 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
BR9916327A (pt) 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
KR20010108024A (ko) 1998-12-17 2001-12-07 프리돌린 클라우스너, 롤란드 비. 보레르 단백질 키나제 억제제로서의 4,5-피라진옥신돌
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
EP1630559A3 (en) * 1998-12-30 2006-06-07 Sugen, Inc. PYK2 (RAFTK) and inflammation
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
EP1165513A1 (en) * 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
PL350891A1 (en) * 1999-04-06 2003-02-10 Knoll Gmbh Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1222273A2 (en) 1999-10-22 2002-07-17 PHARMACIA & UPJOHN COMPANY Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
ATE331514T1 (de) 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
JP2003535038A (ja) * 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
EP1259514B9 (en) 2000-02-28 2005-11-09 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US7005444B2 (en) 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
AU2002341881B2 (en) 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
BR0213185A (pt) 2001-10-10 2004-09-14 Sugen Inc Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
WO2003082869A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
CA2481036C (en) * 2002-04-03 2012-05-29 Allergan, Inc. (3z)-(3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
IL165392A0 (en) 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US6699863B1 (en) 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
WO2005016875A2 (en) 2003-08-06 2005-02-24 Sugen, Inc. Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005113561A1 (en) * 2004-05-20 2005-12-01 Sugen, Inc. Cyclicsulfonate pyrrole indolinones as kinase inhibitors
JP2008503473A (ja) * 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
WO2006106437A2 (en) 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US7846941B2 (en) * 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1962851A2 (en) * 2005-12-22 2008-09-03 SmithKline Beecham Corporation Compounds
US8367664B2 (en) 2006-01-24 2013-02-05 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
EP2099757B1 (en) 2006-11-16 2014-06-25 Allergan, Inc. Sulfoximines as kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2008127199A1 (en) 2007-04-13 2008-10-23 Agency For Science, Technology And Research Methods of controlling tumorigenesis and diagnosing the risk thereof
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN101909630A (zh) 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US20090301928A1 (en) * 2008-06-05 2009-12-10 United Comb & Novelty Corporation Packaging For Lipped Containers
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
AU2010289353B2 (en) 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US20130035325A1 (en) * 2009-11-16 2013-02-07 The Regents Of The University Of California Kinase inhibitors
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
CA3067746A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
WO2022006040A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009598A1 (en) * 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.

Also Published As

Publication number Publication date
MY109695A (en) 1997-04-30
WO1994014808A1 (en) 1994-07-07
CA2126228A1 (en) 1994-07-07
ZA939578B (en) 1994-08-11
AU5810594A (en) 1994-07-19
GB9226855D0 (en) 1993-02-17
DE69325262T2 (de) 2000-01-20
RU94040390A (ru) 1997-05-27
JPH07504208A (ja) 1995-05-11
NZ259330A (en) 1995-12-21
EP0626963B1 (en) 1999-06-09
DK0626963T3 (da) 1999-12-13
EP0626963A1 (en) 1994-12-07
IL108087A0 (en) 1994-04-12
FI943838A7 (fi) 1994-08-19
IL108087A (en) 1997-09-30
AU670488B2 (en) 1996-07-18
TW296383B (es) 1997-01-21
HU9401950D0 (en) 1994-09-28
ATE181074T1 (de) 1999-06-15
GR3030941T3 (en) 1999-11-30
DE69325262D1 (de) 1999-07-15
CN1093707A (zh) 1994-10-19
JP3507497B2 (ja) 2004-03-15
KR950700296A (ko) 1995-01-16
PL304894A1 (en) 1995-01-09
MX9400206A (es) 1994-07-29
FI943838A0 (fi) 1994-08-19
HUT67431A (en) 1995-04-28
US5397787A (en) 1995-03-14

Similar Documents

Publication Publication Date Title
ES2134926T3 (es) Derivados vinileno-azaindolicos y su procedimiento de preparacion.
ES2055056T3 (es) Derivados de pirimidopirimidina.
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
MX9300786A (es) Compuestos hipolipidaemicos.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation
ES2059873T3 (es) 2-alquinilfenoles sustituidos con actividad antiinflamatoria, un procedimiento para su preparacion y sus composiciones farmaceuticas.
AR005229A1 (es) Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende.
ES8106291A1 (es) Procedimiento para preparar derivados de 3-aminoproxiarilo
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX9602979A (es) Compuestos heterociclicos terapeuticos.
ES2071666T3 (es) Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9504895A (es) Derivados de beta-aril- y beta-heteroaril-alfa- cianoacrilamida n-substituidos y proceso para su preparacion.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2012648A6 (es) Procedimiento para la preparacion de nuevos derivados de 1,4-benzoxazina y 1,4-benzotiazina.
ES2152237T3 (es) Pirazolo(4,3-c)piridinas, un procedimiento para su preparacion y su uso como inhibidores de la recaptacion de serotonina.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
PT83726B (pt) Processo para preparacao de derivados da beta-carbolina substituidas por grupos fenoxi e de composicoes farmaceuticas que os contem
AR008244A1 (es) Compuestos heterociclicos, procedimiento para prepararlos, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
CO4230234A1 (es) DERIVADOS DE 6-(HIDROXIFENIL)SULFONIL-BENZO[b]PIRANO, COMPO- SICIONES QUE CONTIENEN TALES DERIVADOS, USOS DE LOS MISMOS, PROCEDIMIENTOS DE PREPARACION E INTERMEDIOS EMPLEADOS EN LA PREPARACION DE TALES DERIVADOS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 626963

Country of ref document: ES